All In MedTech

Device Trial Radar · NCT05114135

TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study)

First-in-man Safety and Performance of OSTEO3 ZP PUTTY in Subjects Undergoing Transforaminal Lumbar Interbody Fusion

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Sep 7, 2021

Primary completion

Apr 20, 2023

Study completion Mar 14, 2024

Sponsor

Lead sponsor
OssDsignNot on our public-company list
Sponsor type
Industry
First posted
Nov 9, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In recent years there has been an increase in interest from surgeons in the use of synthetic bone graft substitutes to avoid the need of sourcing allograft or iliac crest autograft for use in spinal fusion procedures. This will be an open label, prospective, first in man, single-centre clinical study to evaluate the safety and performance of Osteo3 ZP Putty synthetic bone graft in TLIF procedures with instrumented PLF. Safety and performance data obtained in this clinical study will be used to estimate clinical success rates achieved with the use of Osteo3 ZP Putty synthetic bone graft in TLIF procedures. No comparative control group is intended. The study is expected to run for approximately three years with each subject being followed up for a two- year post-operative period. The target is to recruit approximately 17 subjects to this clinical study, allowing for some subject attrition to get 15 evaluable.

Conditions

  • Degenerative Disc Disease
  • Degenerative Spondylolisthesis
  • Lumbar Spinal Stenosis

Interventions

  • Osteo3 ZP PuttyDevice

    Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of device-related serious adverse eventsTime frame: 24 months
  2. Percentage of subjects with evidence of interbody fusion being achieved in 12 months post-surgeryTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Buda Health Center, Királyhágó u. 1-3.

    Budapest, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.